Cancer Research
FDA Fast-Tracks Zongertinib for HER2-Mutated Lung Cancer in February 2026
New targeted therapy receives accelerated approval for specific non-small cell lung cancer subtype with HER2 mutations.
Drug Approval
Apr 3, 2026 0
2 articles in this topic
New targeted therapy receives accelerated approval for specific non-small cell lung cancer subtype with HER2 mutations.
New targeted therapy offers hope for patients with specific genetic mutations in advanced non-small cell lung cancer.